ORI Capital financing of Orchard Therapeutics

BDO provided due diligence services to ORI Capital in their financing of Orchard Therapeutics. Orchard Therapeutics, a biotechnology company dedicated to transforming the lives of patients with rare disorders through innovative gene therapies, announced the completion of an oversubscribed $110 million (£85 million) Series B financing. Baillie Gifford and ORI Capital co-led the financing. Significant new investments from Temasek and Cowen Healthcare Investments, alongside Juda Capital, Pavilion Capital, RTW Investments, Agent Capital, 4BIO Capital and existing investors F-Prime Capital and UCL Technology Fund completed the financing.